Published in
Taylor and Francis Group, Human Vaccines and Immunotherapeutics, 5(18), 2022
DOI: 10.1080/21645515.2022.2044255
Links
Tools
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
Journal article published in 2022 by
Anna Lisa Ong-Lim,
Georgi Shukarev,
Mitzi Trinidad-Aseron,
Delia Caparas-Yu,
Astrid Greijer,
Michel Duchene,
Gert Scheper,
Vitalija van Paassen,
Mathieu Le Gars,
Conor P. Cahill 
,
Hanneke Schuitemaker ,
Macaya Douoguih,
Jeanne-Marie Jacquet
,
Hanneke Schuitemaker ,
Macaya Douoguih,
Jeanne-Marie Jacquet
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 